cytarabine has been researched along with Encephalopathy, Toxic in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (40.00) | 29.6817 |
| 2010's | 12 (48.00) | 24.3611 |
| 2020's | 2 (8.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huitema, ADR; Otten, HM; Verkerk, K | 1 |
| Khodadoost, A; Kiani, A; Nik, SH; Pourahmad, J; Salimi, A | 1 |
| Englander, EW; Gorgun, MF; Zhuo, M | 1 |
| Dotson, JL; Jamil, MO | 1 |
| Chen, J; Ngo, D; Rosenthal, J | 1 |
| Morgensztern, D; Peddi, PF; Peddi, S; Santos, ES | 1 |
| Ambrosetti, A; Balzarotti, M; Binder, M; Cavalli, F; Cwynarski, K; Deckert, M; Fabbri, A; Ferrari, A; Ferreri, AJ; Finke, J; Fox, CP; Gørløv, JS; Hemmaway, C; Hertenstein, B; Hess, G; Illerhaus, G; Johnson, P; Keller, U; Krause, SW; Levis, A; Linton, KM; Panse, J; Pisani, F; Politi, LS; Ponzoni, M; Pukrop, T; Pulczynski, E; Reni, M; Rosée, PL; Roth, A; Rudà, R; Schmoll, HJ; Schorb, E; Stilgenbauer, S; Torri, V; Tucci, A; Zucca, E | 1 |
| Abrahamsson, J; Åsberg, A; Grell, K; Harila-Saari, A; Heldrup, J; Jonsson, OG; Levinsen, M; Risteli, J; Schmiegelow, K; Taskinen, M; Vettenranta, K | 1 |
| Bajwa, RPS; Gerhardt, CA; Hagedoorn, M; Keim, MC; Lehmann, V; Olshefski, RS; Tuinman, MA; Winning, AM | 1 |
| Ehninger, G; Hiddemann, W; Illmer, T; Karsch, C; Kiani, A; Lindner, LH; Ostermann, H; Platzbecker, U; Schleyer, E; Würfel, M | 1 |
| Cain, M; Cull, GM; Hackett, LP; Ilett, KF; Radeski, D | 1 |
| Dürken, M; Karremann, M; Neumaier-Probst, E; von Komorowski, G | 1 |
| Braunagel, D; Dransfeld, CL; Ehninger, G; Kramer, M; Mahlknecht, U; Schaich, M | 1 |
| Chary, NR; Jena, G; Patel, RS; Rachamalla, M; Shera, FY; Tikoo, K | 1 |
| Chamberlain, MC | 1 |
| Dorgeret, S; Duval, M; Legrand, F; Saizou, C; Vilmer, E | 1 |
| Jain, S; Kumari, S; Lal, V; Mahi, S; Malhotra, P; Varma, S | 1 |
| Brevet, M; Damaj, G; Garidi, R; Gruson, B; Royer, B; Vaida, I | 1 |
| Donadio, A; Dossa, D; Jean, R; Margueritte, G; Montoya, F; Navarro, M; Rieu, D | 1 |
| Ito, M; Kamijo, A; Maruta, I; Mizuno, Y; Onishi, H; Onose, M; Saito, H; Yamada, T | 1 |
| Hattori, N; Kawakami, K; Nakamaki, T; Nakashima, H; Saito, B; Tomoyasu, S; Usui, T | 1 |
| Becker, A; Bode, U; Jaehde, U; Linnebank, M; Pels, H; Schlegel, U; Vezmar, S | 1 |
| Hensley, ML; Larson, RA; Peterson, B; Schiffer, CA; Silver, RT; Szatrowski, TP | 1 |
| Dastidar, P; Frey, H; Hietaharju, A; Honkaniemi, J; Kähärä, V; Kellokumpu-Lehtinen, P; Keskinen, L; Latvala, M; Ollikainen, J; Salonen, T; Vähämäki, L | 1 |
| Brant, J; Nielsen, E | 1 |
2 review(s) available for cytarabine and Encephalopathy, Toxic
| Article | Year |
|---|---|
Central nervous system toxicities of chemotherapeutic agents.
Topics: Antineoplastic Agents; Central Nervous System Diseases; Cisplatin; Cytarabine; Fluorouracil; Humans; Ifosfamide; Methotrexate; Neurotoxicity Syndromes; Posterior Leukoencephalopathy Syndrome; Vidarabine; Vincristine | 2014 |
Chemotherapy-induced neurotoxicity: assessment and interventions for patients at risk.
Topics: Antineoplastic Agents; Cisplatin; Cytarabine; Humans; Ifosfamide; Methotrexate; Neoplasms; Neurotoxicity Syndromes; Nursing Assessment; Oncology Nursing; Paclitaxel; Vinca Alkaloids | 2002 |
5 trial(s) available for cytarabine and Encephalopathy, Toxic
| Article | Year |
|---|---|
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.
Topics: Acute Kidney Injury; Anemia; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Comparative Effectiveness Research; Cytarabine; Death, Sudden; Denmark; Dexamethasone; Disease-Free Survival; Female; Follow-Up Studies; Gastrointestinal Diseases; Germany; Heart Injuries; Hematopoietic Stem Cell Transplantation; Humans; Hyperglycemia; Induction Chemotherapy; Infections; Intraocular Lymphoma; Italy; Kaplan-Meier Estimate; Lymphoma, B-Cell; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Mucositis; Neurotoxicity Syndromes; Neutropenia; Optic Nerve Neoplasms; Poisoning; Radiotherapy, Adjuvant; Remission Induction; Rituximab; Stroke; Switzerland; Thiotepa; Thrombocytopenia; Thrombosis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; United Kingdom | 2016 |
Efficacy and Toxicity of Intrathecal Liposomal Cytarabine in First-line Therapy of Childhood Acute Lymphoblastic Leukemia.
Topics: Adolescent; Child; Child, Preschool; Cytarabine; Dexamethasone; Disease-Free Survival; Female; Humans; Infant; Injections, Spinal; Liposomes; Maintenance Chemotherapy; Male; Neurotoxicity Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Scandinavian and Nordic Countries | 2016 |
The T_T genotype within the NME1 promoter single nucleotide polymorphism -835 C/T is associated with an increased risk of cytarabine induced neurotoxicity in patients with acute myeloid leukemia.
Topics: Acetylcysteine; Adolescent; Adult; Aged; Apoptosis; Cytarabine; Female; Genotype; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neurons; Neurotoxicity Syndromes; NM23 Nucleoside Diphosphate Kinases; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Retrospective Studies; Survival Rate; Young Adult | 2012 |
First-line autologous stem cell transplantation in primary CNS lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms; Combined Modality Therapy; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunocompetence; Lymphoma; Male; Melphalan; Middle Aged; Neurotoxicity Syndromes; Radiotherapy, Adjuvant; Recurrence; Remission Induction; Survival Rate; Transplantation, Autologous | 2005 |
Marked elevation in homocysteine and homocysteine sulfinic acid in the cerebrospinal fluid of lymphoma patients receiving intensive treatment with methotrexate.
Topics: Adult; Aged; Alleles; Antimetabolites, Antineoplastic; Brain Chemistry; Central Nervous System Neoplasms; Cytarabine; Excitatory Amino Acids; Female; Homocysteine; Humans; Injections, Intravenous; Injections, Intraventricular; Lymphoma; Male; Methotrexate; Middle Aged; Neurotoxicity Syndromes; Pilot Projects; S-Adenosylmethionine; Statistics, Nonparametric; Time Factors | 2007 |
18 other study(ies) available for cytarabine and Encephalopathy, Toxic
| Article | Year |
|---|---|
Idiopathic hyperammonemic encephalopathy secondary to gemcitabine-cisplatin treatment.
Topics: Antineoplastic Agents; Asparaginase; Brain Diseases; Cisplatin; Cytarabine; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Hyperammonemia; Neurotoxicity Syndromes | 2022 |
Trifluoperazine an Antipsychotic Drug and Inhibitor of Mitochondrial Permeability Transition Protects Cytarabine and Ifosfamide-Induced Neurotoxicity.
Topics: Animals; Antineoplastic Agents; Brain; Cells, Cultured; Cytarabine; Disease Models, Animal; Humans; Ifosfamide; Lipid Peroxidation; Membrane Potential, Mitochondrial; Mitochondria; Neurons; Neuroprotective Agents; Neurotoxicity Syndromes; Oxidative Stress; Primary Cell Culture; Rats; Rats, Wistar; Reactive Oxygen Species; Trifluoperazine | 2020 |
Neurotoxicity of cytarabine (Ara-C) in dorsal root ganglion neurons originates from impediment of mtDNA synthesis and compromise of mitochondrial function.
Topics: Animals; Antimetabolites, Antineoplastic; Cells, Cultured; Cytarabine; DNA Damage; DNA, Mitochondrial; Ganglia, Spinal; Male; Mice; Mice, Inbred C57BL; Mitochondria; Neurotoxicity Syndromes; Signal Transduction | 2018 |
Successful treatment of cytarabine-related neurotoxicity with corticosteroids, a case series.
Topics: Adrenal Cortex Hormones; Adult; Aged; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Neurotoxicity Syndromes | 2018 |
Case report of neurotoxicity with blinatumomab and concurrent intrathecal chemotherapy in second relapse of acute lymphoblastic leukemia with central nervous system disease.
Topics: Adult; Antibodies, Bispecific; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Diseases; Cytarabine; Humans; Hydrocortisone; Male; Methotrexate; Neurotoxicity Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence | 2019 |
Psychosexual development and satisfaction in long-term survivors of childhood cancer: Neurotoxic treatment intensity as a risk indicator.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Case-Control Studies; Cranial Irradiation; Cytarabine; Female; Humans; Injections, Spinal; Leukemia; Lymphoma; Male; Methotrexate; Neoplasms; Neurotoxicity Syndromes; Orgasm; Personal Satisfaction; Psychosexual Development; Reproductive Health; Risk Factors; Sexual Partners; Surveys and Questionnaires; Survivors; Thiotepa; Young Adult | 2017 |
AraU accumulation in patients with renal insufficiency as a potential mechanism for cytarabine neurotoxicity.
Topics: Aged; Antimetabolites, Antineoplastic; Arabinofuranosyluracil; Cytarabine; Female; Half-Life; Humans; Kidney Failure, Chronic; Leukemia, Myeloid, Acute; Male; Middle Aged; Neurotoxicity Syndromes | 2008 |
Effective clearance of Ara-U the major metabolite of cytosine arabinoside (Ara-C) by hemodialysis in a patient with lymphoma and end-stage renal failure.
Topics: Antimetabolites, Antineoplastic; Arabinofuranosyluracil; Chromatography, High Pressure Liquid; Cytarabine; Female; Humans; Kidney Failure, Chronic; Lymphoma, Mantle-Cell; Middle Aged; Neurotoxicity Syndromes; Renal Dialysis | 2011 |
[Hemiparesis in acute lymphoblastic leukemia].
Topics: Adolescent; Antimetabolites, Antineoplastic; Brain; Cytarabine; Diffusion Magnetic Resonance Imaging; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Injections, Spinal; Methotrexate; Neurologic Examination; Neurotoxicity Syndromes; Paresis; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2010 |
Cytarabine induced cerebellar neuronal damage in juvenile rat: correlating neurobehavioral performance with cellular and genetic alterations.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Behavior, Animal; Calbindins; Caspase 3; Cerebellum; Cytarabine; DNA Damage; Dose-Response Relationship, Drug; Histones; Male; Nerve Tissue Proteins; Neurotoxicity Syndromes; Organ Size; Oxidative Stress; Psychomotor Performance; Purkinje Cells; Random Allocation; Rats; Rats, Sprague-Dawley; S100 Calcium Binding Protein G; Tumor Suppressor Protein p53 | 2012 |
Neurotoxicity of intra-CSF liposomal cytarabine (DepoCyt) administered for the treatment of leptomeningeal metastases: a retrospective case series.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Cytarabine; Disease Progression; Female; Follow-Up Studies; Humans; Injections, Spinal; Liposomes; Magnetic Resonance Imaging; Male; Meningeal Neoplasms; Middle Aged; Neoplasm Staging; Neoplasms; Neurotoxicity Syndromes; Prognosis; Prospective Studies; Retrospective Studies | 2012 |
Cerebellar herniation after intrathecal chemotherapy including cytosine arabinoside in a boy with T acute lymphoblastic leukemia.
Topics: Antineoplastic Agents; Child; Cytarabine; Encephalocele; Humans; Injections, Spinal; Leukemia-Lymphoma, Adult T-Cell; Male; Neurotoxicity Syndromes; Radiography | 2002 |
Cytarabine-induced neurotoxicity responding to methyl prednisolone.
Topics: Adult; Antimetabolites, Antineoplastic; Cytarabine; Fatal Outcome; Female; Humans; Injections, Intravenous; Leukemia, Myeloid, Acute; Methylprednisolone; Neurotoxicity Syndromes | 2004 |
[Subacute encephalopathy of early onset during treatment of relapse of lymphoblastosis in a young infant].
Topics: Antineoplastic Combined Chemotherapy Protocols; Atrophy; Brain; Cerebellum; Cerebral Ventricles; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Epilepsy; Humans; Infant; Injections, Spinal; Leukemia, Lymphoid; Male; Neurotoxicity Syndromes; Paraventricular Hypothalamic Nucleus; Recurrence; Remission Induction | 1977 |
Conversion disorder with convulsion and motor deficit mimicking the adverse effects of high-dose Ara-C treatment in a posttransplant acute myeloid leukemia patient: a case report and review of the literature.
Topics: Acute Disease; Adult; Antimetabolites, Antineoplastic; Bone Marrow Transplantation; Conversion Disorder; Cytarabine; Diagnosis, Differential; Female; Humans; Leukemia, Myeloid; Neurotoxicity Syndromes; Psychomotor Performance; Seizures | 2004 |
Reversible posterior leukoencephalopathy syndrome after repeat intermediate-dose cytarabine chemotherapy in a patient with acute myeloid leukemia.
Topics: Antimetabolites, Antineoplastic; Brain Diseases; Cytarabine; Drug Hypersensitivity; Humans; Leukemia, Monocytic, Acute; Male; Middle Aged; Neurotoxicity Syndromes; Syndrome | 2007 |
Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia: analysis of Cancer and Leukemia Group B 9013.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Cohort Studies; Cytarabine; Female; Humans; Interferon alpha-2; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Logistic Models; Male; Mental Disorders; Middle Aged; Multivariate Analysis; Neurotoxicity Syndromes; Recombinant Proteins; Regression Analysis; Risk Factors | 2000 |
Reversible posterior leukoencephalopathy after combination chemotherapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophosphamide; Cytarabine; Doxorubicin; Female; Humans; Injections, Spinal; Leukocytes; Magnetic Resonance Imaging; Neurotoxicity Syndromes; Steroids | 2000 |